Press Releases

« Back
Printer Friendly Version View printer-friendly version

Selecta Biosciences to Present New Five Monthly Dose Phase 2 Data for SEL-212 in Chronic, Severe Gout at Upcoming 2018 ACR Annual Meeting

  • Data continue to suggest sustained serum uric acid (sUA) level reductions and low number of flares over five months of treatment
  • Results correlated with low or no anti-drug antibodies (ADAs) against the pegsiticase enzyme
  • Company to host conference call and live webcast on October 23 to discuss the data

WATERTOWN, Mass., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that new data from the ongoing Phase 2 study of SEL-212 in chronic, severe gout will be presented at the upcoming 2018 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, from October 19-23, 2018 in Chicago.

“We continue to be impressed by the potential of SEL-212 to control uric acid levels and reduce the number of gout flares experienced by patients with chronic, severe gout,” said Werner Cautreels, Ph.D., president and CEO of Selecta. “The concurrent mitigation of ADAs and monthly dosing regimen has the potential to differentiate SEL-212 from other uric acid lowering treatments and offers the possibility for a more sustained effect.”

Abstracts to be presented include:

  • Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with SVP-Rapamycin Enables Sustained Reduction of Acute Gout Flares; Monday, October 22; 9:00 a.m.-11:00 a.m. CT
  • Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Measurement of Dissolution of Urate Deposits Associated with Monthly Dosing of a Pegylated Uricase (Pegadricase) with SVP-Rapamycin By Dual Energy Computed Tomography; Tuesday, October 23; 9:00 a.m.-11:00 a.m. CT
  • Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: SVP-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing; Tuesday, October 23; 9:00 a.m.-11:00 a.m. CT
  • Mitigation of Inflammation Induced By Monosodium Urate Crystals in Mice By Treatment with SVP-Rapamycin; Tuesday, October 23; 9:00 a.m.-11:00 a.m. CT

At 8:00 a.m. ET on Tuesday, October 23, 2018 the company will host a conference call via live webcast. The live webcast of the presentation can be accessed via the Investors & Media section of the company’s website, http://selectabio.com. Individuals may also participate in the live call via telephone by dialing 1-844-845-4170 (domestic) or 1-412-717-9621 (international) and may access a teleconference replay for one week by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using confirmation code 10124095.

About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapeutic candidates. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. A Phase 1 trial is ongoing for a combination therapeutic candidate consisting of SVP-Rapamycin and LMB-100 (Selecta’s SEL-403 product candidate) for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.

Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the company’s plans to present at the American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, whether SEL-212 mitigates immunogenicity and enables sustained reduction of serum uric acid levels, low rate of gout flares and monthly dosing, the ability of SVP-Rapamycin to mitigate inflammation induced by monosodium urate crystals, whether SEL-212 may be differentiated from, and offers the possibility for a more sustained effect as compared to, other uric acid lowering treatments, whether monthly dosing of SEL-212 leads to significant reduction in uric acid deposits,the potential of SEL-212 to treat chronic severe gout patients and resolve their debilitating symptoms, the progress of the Phase 1 trial for SEL-403, the company’s ability to unlock the full potential of biologic therapies by mitigating unwanted immune responses, the company’s plan to apply its SVP platform to a range of biologics for rare and serious diseases, the potential treatment applications for products utilizing the SVP platform in areas such as enzyme therapy, gene therapy, oncology therapy, vaccines and treatments for allergies and autoimmune diseases, the potential of the company’s gene therapy product candidates to treat rare inborn errors of metabolism and enable repeat administration, the potential of the SVP-Rapamycin platform generally, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including their uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the unproven approach of the company’s SVP technology, potential delays in enrollment of patients, undesirable side effects of the company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, substantial fluctuation in the price of its common stock, and other important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on August 8, 2018, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.

ContactInformation:
John Leaman
Selecta Biosciences, Inc.
617-231-8081
jleaman@selectabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com

 

Selecta Biosciences logo.jpg

 

Source: Selecta Biosciences, Inc.